Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Eiji Sunahara is active.

Publication


Featured researches published by Eiji Sunahara.


Cancer Research | 2010

Abstract 3951: EphA10 exhibits anti-apoptotic activity through its dominant-negative role for EphA signaling in cancer cells

Shuji Sato; Hiroshi Tanaka; Yuichi Hikichi; Eiji Sunahara; Isao Kaieda; Takafumi Ishii; Koji Yoshimura

Eph receptors are members of receptor tyrosine kinase family. They are activated by binding of their ligands, ephrins, which regulate numerous physiological responses, including axon guidance, and pattern formation during development. In addition to their important roles during development, several members of the Eph receptor family have been reported to function in carcinogenesis. Recently EphA10 was isolated as the 16th member of the Eph receptor family. EphA10 is expressed in normal testis and binds to ephrin-A. However, biological functions of EphA10 remain unclear. We demonstrate here that EphA10 functions as a dominant-negative receptor for EphA signaling. Our results show that EphA10 is over-expressed in cancer tissues, especially breast and lung cancer tissues as compared with patient-matched adjacent normal tissues. EphA10 binds to ephrin-A2, 3, 4, and 5. Analysis of the amino acid sequence of EphA10 revealed that EphA10 does not have Lys and Asp in the kinase domain, which are necessary for kinase activity nor two Tyr in the juxtamembrane domain, which are necessary for phosphorylation. As expected from the amino acid sequence, no intrinsic tyrosine kinase activity of EphA10 was detected despite its interaction with ephrin-A. To further investigate the mechanism of EphA10 signaling, we tested the role of EphA10 in modulating ephrin-A4 activity. In our experiment, ephrin-A4 suppressed phosphorylation of ERK1/2 in HEK293 cells. EphA10 over-expression in HEK293 cells reduced the effect of ephrin-A4 on ERK1/2. Conversely, reduction of EphA10 expression by antisense oligonucleotides induced apoptosis in the breast cancer cell line ZR-75-1. In addition to its role in shunting ephrin-A response through binding to ephrin-A directly, we found that EphA10 formed a hetero-complex with functional EphA7, suggesting that EphA10 may block EphA signaling by forming non-functional hetero complexes with other functional EphA receptors. Our studies demonstrated that EphA10 has anti-apoptotic function in cancer cells by blocking EphA signaling through its dominant-negative activity. Thus, EphA10 potentially plays an important role in cancer cell survival. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3951.


Archive | 2003

NOVEL PROTEINS AND USE THEREOF

Eiji Sunahara; Takafumi Ishii; Koji Yamamoto; Shuji Sato


Archive | 2006

Prophylactic/therapeutic agent for cancer

Shinichi Kondo; Eiji Sunahara; Toshimitsu Arai; Hiroko Utsumi


Archive | 2004

Preventive/remedy for cancer

Eiji Sunahara; Takafumi Ishii


Archive | 2001

Novel protein, process for producing the same and use thereof

Takafumi Ishii; Eiji Sunahara


Archive | 2005

NOVEL PROTEIN COMPLEX AND USE THEREOF

Eiji Sunahara; Takafumi Ishii


Archive | 2002

Novel receptor protein and dna thereof

Koji Yoshimura; Shuji Sato; Takafumi Ishii; Eiji Sunahara


Archive | 2007

Isolated human protein having esterase activity and DNA encoding the same

Ryuichi Tozawa; Eiji Sunahara; Yoshio Taniyama


Archive | 2006

Agent prophylactique/thérapeutique pour le cancer

Shinichi Kondo; Eiji Sunahara; Toshimitsu Arai; Hiroko Utsumi


Archive | 2002

Nouvelle proteine receptrice et son adn

Koji Yoshimura; Shuji Sato; Takafumi Ishii; Eiji Sunahara

Collaboration


Dive into the Eiji Sunahara's collaboration.

Top Co-Authors

Avatar

Takafumi Ishii

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Shuji Sato

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Koji Yoshimura

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Hiroko Utsumi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Ryuichi Tozawa

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Shinichi Kondo

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Toshimitsu Arai

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Yoshio Taniyama

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Hiroshi Tanaka

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Isao Kaieda

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge